Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 May 7;13(5):e14010.
doi: 10.15252/emmm.202114010. Epub 2021 Mar 29.

Therapy resistance on the RADar in ovarian cancer

Jonas Schwickert  1   2   3 , Franziska M Zickgraf  1   2 , Martin R Sprick  1   2
Affiliations
Comment

Therapy resistance on the RADar in ovarian cancer

Jonas Schwickert et al. EMBO Mol Med. .

Abstract

Ovarian cancer has the worst prognosis of all gynecological cancers with high-grade serous ovarian cancer (HGSOC) accounting for the majority of ovarian cancer deaths. Therapy resistance and the selection of effective therapies for patients remains a major challenge. In this issue of EMBO Molecular Medicine, Hoppe et al present RAD51 expression as a biomarker of platinum resistance in high-grade serous ovarian cancer (HGSOC) patients (Hoppe et al, 2021).

PubMed Disclaimer

Figures

Figure 1
Figure 1. Ovarian cancer patients can be subdivided into two groups based on their HRD status
By defining the RAD51NES, it is possible to stratify HRD‐negative patients undergoing platinum‐based therapy for clinical outcome.
See this image and copyright information in PMC

Comment on

  • Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer.
    Hoppe MM, Jaynes P, Wardyn JD, Upadhyayula SS, Tan TZ, Lie S, Lim DGZ, Pang BNK, Lim S, P S Yeong J, Karnezis A, Chiu DS, Leung S, Huntsman DG, Sedukhina AS, Sato K, Topp MD, Scott CL, Choi H, Patel NR, Brown R, Kaye SB, Pitt JJ, Tan DSP, Jeyasekharan AD. Hoppe MM, et al. EMBO Mol Med. 2021 May 7;13(5):e13366. doi: 10.15252/emmm.202013366. Epub 2021 Mar 11. EMBO Mol Med. 2021. PMID: 33709473 Free PMC article.

References

    1. Baumann P, West SC (1998) Role of the human RAD51 protein in homologous recombination and double‐stranded‐break repair. Trends Biochem Sci 23: 247–251 - PubMed
    1. Cancer Genome Atlas Research N (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609–615 - PMC - PubMed
    1. Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD (2018) Biomarkers for Homologous Recombination Deficiency in Cancer. J Natl Cancer Inst 110: 704–713 - PubMed
    1. Hoppe MM, Jaynes P, Wardyn JD, Srinivas US, Tan TZ, Lie S, Lim DGZ, Pang BNK, Lim S, Yeong JPS et al (2021) Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer. EMBO Mol Med 13: e13366 - PMC - PubMed
    1. Kandalaft LE, Odunsi K, Coukos G (2019) Immunotherapy in ovarian cancer: are we there yet? J Clin Oncol 37: 2460–2471 - PubMed